2-amino-5-ureidopentanamide and Epilepsy--Temporal-Lobe

Epilepsy is considered as one of the major disabling neuropathologies. Almost one third of adult patients with temporal lobe epilepsy (TLE) do not respond to current antiepileptic drugs (AEDs). Additionally, most AEDs do not have neuroprotective effects against the inherent neurodegenerative process underlying the hippocampal sclerosis on TLE. Dysfunctions in the GABAergic neurotransmission may contribute not only to the onset of epileptic activity but also constitute an important system for therapeutic approaches. Therefore, molecules that enhance GABA inhibitory effects could open novel avenues for the understanding of epileptic plasticity and for drug development. Parawixin2, a compound isolated from

Topics: Animals; Disease Models, Animal; Epilepsy, Temporal Lobe; Hippocampus; Male; Neurons; Neuroprotective Agents; Rats, Wistar; Spider Venoms; Urea

(1)

Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy, Temporal Lobe; Hippocampus; Lithium; Male; Neurons; Neuroprotective Agents; Neurotransmitter Uptake Inhibitors; Nipecotic Acids; Pilocarpine; Rats, Wistar; Spider Venoms; Tiagabine; Urea